Literature DB >> 19220758

Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study.

F Bär1, H Von Koschitzky, U Roblick, H P Bruch, L Schulze, U Sonnenborn, M Böttner, T Wedel.   

Abstract

Abstract Clinical studies have shown that probiotics influence gastrointestinal motility, e.g. Escherichia coli Nissle 1917 (EcN) (Mutaflor) proved to be at least as efficacious as lactulose and more potent than placebo in constipated patients. As the underlying mechanisms are not clarified, the effects of EcN culture supernatants on human colonic motility were assessed in vitro. Human colonic circular smooth muscle strips (n = 94, 17 patients) were isometrically examined in an organ bath and exposed to different concentrations of EcN supernatants. Contractility responses were recorded under (i) native conditions, (ii) electrical field stimulation (EFS), (iii) non-adrenergic non-cholinergic conditions, and (iv) enteric nerve blockade by tetrodotoxin (TTX). As concentrations of acetic acid were increased in EcN supernatants, contractility responses to acetic acid were additionally tested. EcN supernatants significantly increased the maximal tension forces both at low and high concentrations. Neither blockade of both adrenergic and cholinergic nerves nor application of TTX abolished these effects. EFS-induced contractility responses were not altered after exposure to EcN supernatants. Acetic acid elicited effects comparable to EcN supernatants only under TTX conditions. EcN supernatants modulate in vitro contractility of the human colon. As neither partial nor TTX blockade of enteric nerves abolished these effects, EcN supernatants appear to enhance colonic contractility by direct stimulation of smooth muscle cells. Active metabolites may include other substances than acetic acid, as acetic acid only partially resembled the effects elicited by EcN supernatants. The data provide a rationale for therapeutical application of probiotics in gastrointestinal motility disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19220758     DOI: 10.1111/j.1365-2982.2008.01258.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  37 in total

1.  Promising discovery of beneficial Escherichia coli in the human gut.

Authors:  Atchareeya Nakkarach; Hooi Ling Foo; Adelene Ai-Lian Song; Sunee Nitisinprasert; Ulaiwan Withayagiat
Journal:  3 Biotech       Date:  2020-06-09       Impact factor: 2.406

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 3.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 4.  Mechanisms of Action of Probiotics and the Gastrointestinal Microbiota on Gut Motility and Constipation.

Authors:  Eirini Dimidi; Stephanos Christodoulides; S Mark Scott; Kevin Whelan
Journal:  Adv Nutr       Date:  2017-05-15       Impact factor: 8.701

Review 5.  Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.

Authors:  Yehuda Ringel; Nitsan Maharshak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-07-25       Impact factor: 4.052

6.  Escherichia coli Nissle 1917-derived factors reduce cell death and late apoptosis and increase transepithelial electrical resistance in a model of 5-fluorouracil-induced intestinal epithelial cell damage.

Authors:  Hanru Wang; Susan E P Bastian; Ker Y Cheah; Andrew Lawrence; Gordon S Howarth
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

Review 7.  Intestinal microbiota and its role in irritable bowel syndrome (IBS).

Authors:  Lena Ohman; Magnus Simrén
Journal:  Curr Gastroenterol Rep       Date:  2013-05

8.  Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.

Authors:  Sylvia Kleta; Marcel Nordhoff; Karsten Tedin; Lothar H Wieler; Rafal Kolenda; Sibylle Oswald; Tobias A Oelschlaeger; Wilfried Bleiss; Peter Schierack
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

9.  Escherichia coli Nissle 1917 protects gnotobiotic pigs against human rotavirus by modulating pDC and NK-cell responses.

Authors:  Anastasia N Vlasova; Lulu Shao; Sukumar Kandasamy; David D Fischer; Abdul Rauf; Stephanie N Langel; Kuldeep S Chattha; Anand Kumar; Huang-Chi Huang; Gireesh Rajashekara; Linda J Saif
Journal:  Eur J Immunol       Date:  2016-08-11       Impact factor: 5.532

Review 10.  Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.

Authors:  Kang Nyeong Lee; Oh Young Lee
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.